as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹1,998.8
Change
+26.9 (1.36%)
Open
₹1,969.0
Prev. Close
₹1,971.9
Day High
₹1,998.9
Day Low
₹1,956.4
Volume Analysis
Traded
362,371
Delivered
213,968
Delivery %
59.05%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (2)
- •Strong return on equity (28.7%)
- •Strong operating margin (30.0%)
Weaknesses (0)
No signal for this stock
Opportunities (3)
- •Strong 3-year EPS growth (131.1%)
- •Strong 3-year revenue growth (18.9%)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹2,055.5 | ₹2,027.2 | ₹2,013.0 | ₹1,984.7 | ₹1,970.5 | ₹1,942.2 | ₹1,928.0 |
| Fibonacci | ₹2,027.2 | ₹2,010.97 | ₹2,000.94 | ₹1,984.7 | ₹1,968.47 | ₹1,958.44 | ₹1,942.2 |
| Camarilla | ₹2,010.49 | ₹2,006.59 | ₹2,002.7 | ₹1,984.7 | ₹1,994.9 | ₹1,991.01 | ₹1,987.11 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
-4.95%
1 Week
-0.8%
1 Month
+1.77%
3 Months
-9.22%
6 Months
-12.4%
1 Year
-1.58%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹1,174.97
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
19.73%
Net margin 16.98% × asset turnover 0.7x × equity multiplier 1.66x
Company Overview
Sector
Healthcare
Market Cap
₹89,994 Cr
P/E (TTM)
16.0
ROE
28.7%
Book Value
₹526.0
Face Value
₹2.0
Source: Screener.in (Consolidated figures) — data as of 18 Nov 2026. Not investment advice.
TopFund Analysis
Lupin Limited holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 76/100. The strongest factor is Financial Strength (100/100), while Momentum (12/100) is the weakest area to weigh before deciding. Notably: Strong return on equity (28.7%); strong operating margin (30.0%). Strong 3-year EPS growth (131.1%).
TopFund Score — Fundamentals Quality
76/100 — GoodData confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company has delivered good profit growth of 37.0% CAGR over last 5 years
- +Company has been maintaining a healthy dividend payout of 17.1%
- +Company's working capital requirements have reduced from 46.4 days to 28.0 days
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Newspaper Publication regarding the Notice of Postal Ballot and Remote E-Voting.
Sandoz launched Lupin’s Ranluspec biosimilar ranibizumab across Europe, excluding Germany, after European Commission approval.
Transcript of Q2 FY2027 Earnings Conference Call.
Copy of Newspaper publication in respect of Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 5,039 | 5,197 | 4,961 | 5,600 | 5,673 | 5,768 | 5,667 | 6,268 | 7,048 | 7,168 | 7,475 | 8,277 | 7,827 |
| Expenses + | 4,121 | 4,159 | 3,964 | 4,359 | 4,332 | 4,412 | 4,346 | 4,541 | 4,706 | 4,906 | 4,989 | 5,827 | 5,783 |
| Operating Profit | 918 | 1,038 | 997 | 1,241 | 1,340 | 1,356 | 1,321 | 1,727 | 2,341 | 2,262 | 2,486 | 2,450 | 2,044 |
| OPM % | 18.0% | 20.0% | 20.0% | 22.0% | 24.0% | 24.0% | 23.0% | 28.0% | 33.0% | 32.0% | 33.0% | 30.0% | 26.0% |
| Other Income + | 40 | 29 | 29 | 68 | 42 | 54 | 57 | 79 | 90 | -312 | 9 | 130 | 127 |
| Interest | 81 | 74 | 71 | 68 | 71 | 67 | 89 | 92 | 108 | 115 | 120 | 110 | 106 |
| Depreciation | 248 | 257 | 457 | 248 | 257 | 271 | 393 | 299 | 317 | 313 | 447 | 453 | 486 |
| Profit before tax | 630 | 736 | 498 | 993 | 1,055 | 1,071 | 896 | 1,416 | 2,007 | 1,522 | 1,928 | 2,017 | 1,580 |
| Tax % | 21.0% | 16.0% | 26.0% | 19.0% | 19.0% | 20.0% | 13.0% | 14.0% | 26.0% | 22.0% | 24.0% | 30.0% | 27.0% |
| Net Profit + | 495 | 619 | 368 | 806 | 859 | 859 | 782 | 1,221 | 1,485 | 1,181 | 1,469 | 1,417 | 1,155 |
| EPS in Rs | 11 | 13 | 8 | 18 | 19 | 19 | 17 | 27 | 32 | 26 | 32 | 31 | 25 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | 22 | 20 | 12 | 16 | 13 | 11 | 14 | 12 | 24 | 24 | 32 | 32 | 11 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 12,770 | 14,256 | 17,367 | 15,797 | 14,665 | 15,375 | 15,163 | 16,405 | 16,642 | 20,011 | 22,708 | 27,958 | 30,746 |
| Expenses + | 9,146 | 10,564 | 12,865 | 12,649 | 12,104 | 13,020 | 12,596 | 16,187 | 14,921 | 16,211 | 17,430 | 19,798 | 21,505 |
| Operating Profit | 3,624 | 3,691 | 4,502 | 3,148 | 2,561 | 2,355 | 2,567 | 219 | 1,721 | 3,800 | 5,278 | 8,160 | 9,241 |
| OPM % | 28.0% | 26.0% | 26.0% | 20.0% | 17.0% | 15.0% | 17.0% | 1.3% | 10.0% | 19.0% | 23.0% | 29.0% | 30.0% |
| Other Income + | 235 | 184 | 106 | -1,310 | 91 | -134 | 138 | 210 | 151 | 131 | 202 | 523 | -45 |
| Interest | 10 | 59 | 153 | 204 | 302 | 363 | 141 | 143 | 274 | 312 | 295 | 434 | 450 |
| Depreciation | 435 | 487 | 912 | 1,086 | 846 | 970 | 887 | 1,659 | 881 | 1,197 | 1,169 | 1,376 | 1,698 |
| Profit before tax | 3,415 | 3,329 | 3,543 | 547 | 1,503 | 887 | 1,676 | -1,372 | 716 | 2,422 | 4,015 | 6,873 | 7,047 |
| Tax % | 28.0% | 32.0% | 28.0% | 53.0% | 59.0% | 130.0% | 27.0% | 10.0% | 38.0% | 20.0% | 18.0% | 22.0% | — |
| Net Profit + | 2,444 | 2,270 | 2,565 | 258 | 615 | -270 | 1,228 | -1,528 | 448 | 1,936 | 3,306 | 5,355 | 5,221 |
| EPS in Rs | 53 | 50 | 57 | 6 | 13 | -6 | 27 | -34 | 9 | 42 | 72 | 117 | 114 |
| Dividend Payout % | 14.0% | 15.0% | 13.0% | 90.0% | 37.0% | -101.0% | 24.0% | -12.0% | 42.0% | 19.0% | 17.0% | 15.0% | — |
| Sales growth | 13 | 12 | 22 | -9 | -7 | 5 | -1 | 8 | 1 | 20 | 13 | 23 | 24 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 8,784 | 11,073 | 13,407 | 13,487 | 13,652 | 12,446 | 13,712 | 12,062 | 12,374 | 14,199 | 17,112 | 22,357 | 23,959 |
| Borrowings + | 537 | 7,178 | 7,966 | 7,143 | 8,496 | 6,305 | 4,783 | 4,158 | 4,542 | 2,922 | 5,448 | 6,616 | 6,180 |
| Other Liabilities + | 3,642 | 3,957 | 4,749 | 5,300 | 5,423 | 5,968 | 4,844 | 5,340 | 5,794 | 6,539 | 6,327 | 9,082 | 9,680 |
| Total Liabilities | 13,054 | 22,298 | 26,212 | 26,020 | 27,661 | 24,810 | 23,430 | 21,651 | 22,800 | 23,751 | 28,978 | 38,146 | 39,911 |
| Fixed Assets + | 4,368 | 8,717 | 11,033 | 10,362 | 11,087 | 7,938 | 7,881 | 7,382 | 8,355 | 8,878 | 9,719 | 10,994 | 13,332 |
| CWIP | 576 | 2,702 | 2,133 | 2,598 | 1,640 | 940 | 1,066 | 1,146 | 1,238 | 773 | 517 | 1,016 | 931 |
| Investments | 1,658 | 16 | 2,136 | 262 | 2,295 | 2,374 | 2,455 | 900 | 517 | 1,075 | 1,146 | 3,670 | 4,456 |
| Other Assets + | 6,451 | 10,862 | 10,910 | 12,798 | 12,639 | 13,557 | 12,028 | 12,224 | 12,690 | 13,026 | 17,596 | 22,466 | 21,191 |
| Total Assets | 13,054 | 22,298 | 26,212 | 26,020 | 27,661 | 24,810 | 23,430 | 21,651 | 22,800 | 23,751 | 28,978 | 38,146 | 39,911 |
| Equity Capital | 90 | 90 | 90 | 90 | 90 | 91 | 91 | 91 | 91 | 91 | 91 | 91 | 91 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 2,733 | -382 | 4,114 | 1,751 | 1,666 | 1,469 | 1,822 | 367 | 1,897 | 3,648 | 3,000 | 7,334 |
| Cash from Investing Activity + | -1,034 | -6,769 | -2,527 | 470 | -3,282 | 1,107 | -1,240 | 1,292 | -1,287 | -1,712 | -4,172 | -3,865 |
| Cash from Financing Activity + | -197 | 5,836 | 433 | -1,492 | 744 | -891 | -1,885 | -1,572 | -337 | -2,184 | 1,732 | -846 |
| Net Cash Flow | 1,502 | -1,315 | 2,019 | 729 | -872 | 1,685 | -1,303 | 87 | 273 | -248 | 560 | 2,624 |
| Free Cash Flow | 1,865 | -6,164 | 1,513 | 261 | 706 | 798 | 1,150 | -531 | 436 | 2,732 | 1,347 | 5,527 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 101 | 21 | 117 | 73 | 102 | 84 | 99 | 146 | 124 | 105 | 74 | 105 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 7.1% | 6.93% | 6.92% | 6.44% | 6.27% | 6.21% | 6.28% | 6.06% | 6.04% | 6.13% | 6.08% | 6.08% |
| Promoters | 47.04% | 47.01% | 46.99% | 46.96% | 46.94% | 46.91% | 46.9% | 46.89% | 46.89% | 46.85% | 46.85% | 46.84% |
| Government | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| FII | 16.11% | 18.29% | 19.32% | 21.5% | 22.04% | 21.46% | 21.25% | 20.5% | 21.5% | 21.7% | 22.42% | 23.28% |
| DII | 29.72% | 27.76% | 26.77% | 25.1% | 24.73% | 25.41% | 25.55% | 26.56% | 25.58% | 25.32% | 24.65% | 23.78% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Lupin Limited (this stock) | 89,994 | 16.0 | 3.75 | 28.7% |
| Manipal Health Enterpri L | 89,630 | 95.6 | 5.36 | 12.7% |
| Max Healthcare Ins Ltd | 99,557 | 70.1 | 8.82 | 14.7% |
| Aurobindo Pharma Ltd | 104,215 | 25.7 | 2.64 | 10.1% |
| Glenmark Pharmaceuticals | 73,937 | 36.5 | 6.59 | 23.6% |
| Mankind Pharma Limited | 108,424 | 46.5 | 6.16 | 13.1% |
| Cipla Ltd | 112,563 | 36.2 | 3.18 | 11.6% |
Which Mutual Funds Hold Lupin Limited?
Frequently Asked Questions about Lupin Limited
Lupin Limited (LUPIN) closed at ₹1,998.8 on NSE on 19 November 2026, up 26.9 (1.36%) from the previous close.
Lupin Limited trades on the NSE (National Stock Exchange of India) under the symbol LUPIN.
Lupin Limited has a trailing twelve-month P/E (price-to-earnings) ratio of 16.0.
Lupin Limited has a dividend yield of 0.91%.
Lupin Limited's 52-week high is ₹2,530.0 and its 52-week low is ₹1,893.0.
Lupin Limited has a market capitalisation of ₹89,994 crore.
Lupin Limited has a TopFund Quality Score of 76/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Lupin Limited?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.